[The rate of antipyrine metabolism in cancer patients administered specific therapy].
Liver monooxygenase (MO) activity was evaluated in 31 children with oncological diseases. The enzyme activity was assessed by measuring the saliva half life of the test drug antipyrine. It was shown that MO activity is reduced in hepatitis, metastatic lesions of the liver, after long-term chemotherapy, combined treatment or progress of disease. Considerable individual variations in MO activity were observed even in cases of comparable pathologies during examinations. It is suggested that therapeutic response in patients with low MO liver levels could be optimized by appropriately stimulating said enzyme system prior to chemotherapy.